Skip to content

Air Barrier System for the Reduction of Airborne Colony-forming Units During Total Shoulder Arthroplasty

Air Barrier System for the Reduction of Airborne Particulate and Colony-forming Units (CFU) During Total Shoulder Arthroplasty.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03782675
Enrollment
40
Registered
2018-12-20
Start date
2019-02-28
Completion date
2019-07-31
Last updated
2018-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis Shoulders

Keywords

Total shoulder replacement, operating room air, surgical site infection, airborne CFU

Brief summary

The objective of this study is to determine whether the Air Barrier System device reduces airborne colony-forming units (e.g., bacteria) present at a surgery site during total shoulder arthroplasty surgeries.

Detailed description

The Air Barrier System (ABS) is a device that uses localized clean air flow to shield a surgery site from ambient airborne contamination. This study examines the hypothesis that the ABS can reduce the presence of airborne CFU and particles at the surgery site during total arthroplasty surgery.

Interventions

DEVICEControl

The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.

The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.

Sponsors

Texas Orthopedic Hospital
CollaboratorUNKNOWN
Nimbic Systems, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Candidate for total shoulder arthroplasty

Exclusion criteria

* Prior history of infection * Revision surgery * Screens positive for MRSA

Design outcomes

Primary

MeasureTime frameDescription
CFU countsFour monthsInter-arm comparison of CFU counts taken during both the Control arm and ABS arm
Particle countsFour monthsInter-arm comparison of particle counts taken during both the Control arm and ABS arm.

Contacts

Primary ContactGregory Stocks, MD
stocks@fondren.com713-799-8600
Backup ContactSean Self
self@nimbicsystems.com284-565-5715

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026